ArticleArthritis research & therapy2026
Synovial fluid potentiates local fibroblasts to drive monocyte activation in juvenile idiopathic arthritis.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSynovial fibroblasts (S-Fib) are recognized as key drivers of joint inflammation in adult arthritis. Moreover, data are limited on the processes driving monocyte activation in oligoarticular juvenile idiopathic arthritis (oJIA). Therefore, we aimed to explore if S-Fib from patients with oJIA induce monocyte activation.
methodsS-Fib were isolated from the synovial fluid (SF) of n = 13 patients with oligoarticular juvenile idiopathic arthritis (oJIA) and n = 4 patients with rheumatoid arthritis (RA) to be used as a disease control. Healthy adult S-Fib were purchased. The interaction between monocytes and S-Fib was studied in co-cultures with monocytes isolated from healthy donors. These cells were analyzed by surface marker expression, cytokine production and T-cell activation. Moreover, S-Fib were “re-introduced” to the inflammatory synovial environment by priming or not with pooled cell-free SF from oJIA patients. The S-Fib were subsequently analyzed by cytokine production, ability to induce immune cell chemotaxis and mass spectrometry for proteomic changes, as well as their ability to induce monocyte activation as above.
resultsCo-culture with S-Fib induced inflammatory activation of healthy monocytes as characterized by increased CD86 and HLA-DR expression, cytokine production and subsequent T-cell activation. Importantly, there were only minor differences in monocyte activation pattern depending on the source of the co-cultured S-Fib (oJIA, RA or healthy). Interestingly, compared to S-Fib alone, priming of S-Fib with a pool of SF induced an inflammatory phenotype, production of IL-6 and enhanced chemotaxis of monocytes. Additionally, primed S-Fib induced a more pronounced inflammatory phenotype in healthy monocytes compared to S-Fib alone. Finally, direct cell-cell contact between S-Fib and monocytes was required for full induction of the observed monocyte activation.
conclusionsOur data show a contact dependent role for S-Fib in driving inflammation in oJIA by inducing pro-inflammatory monocytes, processes potentiated by inflamed SF. These data further support that targeting cell-cell interactions could be a viable option to explore for novel treatment strategies in arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.